Polyrizon announced that it has submitted a pre-submission package to the FDA for its PL-14 Allergy Blocker nasal spray. The company describes the product as “a novel, non-invasive nasal spray that forms a physical barrier designed to provide rapid, long-lasting relief from allergic rhinitis symptoms by blocking allergen entry.”
In 2024, Polyrizon raised $4.2 million for development of its hydrogel nasal delivery technology platforms, including Capture and Contain, a “biological mask”, and Trap and Target, for mucosal adhesion. Earlier this year, the company announced that it would develop an intranasal naloxone product based on Trap and Target.
Polyrizon CEO Tomer Izraeli commented, “We are pleased to submit this Pre-Sub to the FDA, a crucial step in our journey to bring PL-14 Allergy Blocker to market. Allergic rhinitis affects hundreds of millions of people worldwide, and we believe that our innovative approach has the potential to transform treatment options. This submission positions Polyrizon for accelerated development in this high-demand therapeutic area.”
Read the Polyrizon press release
